| All Releases |
|---|
 |
Pharmacyclics Announces Completion of Phase 1 Clinical Trial of Factor VIIa Inhibitor PCI-27483
Nov 25, 2008
|
12.4 KB
|
| |
SUNNYVALE, Calif., Nov 25, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Pharmacyclics, Inc.
(Nasdaq: PCYC) today announced that the company has completed a Phase 1
clinical trial with PCI-27483, the company's novel, first-in-class
small-molecule Factor VIIa inhibitor. The trial was conducted in sixteen (16)
healthy volunteers to evalu...
|
|
|
Pharmacyclics Reports First Quarter Fiscal 2009 Financial Results
Oct 30, 2008
|
12.0 KB
|
| |
SUNNYVALE, Calif., Oct 30, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Pharmacyclics, Inc. (Nasdaq: PCYC) today reported financial results for its first fiscal quarter ended September 30, 2008. The net loss for the first quarter of fiscal 2009, was $6.5 million, or $0.25 per share, compared to a net loss of $6.8 million, or $0.26 per sha...
|
|
|
Pharmacyclics Responds to Nasdaq Letter
Sep 30, 2008
|
8.9 KB
|
| |
SUNNYVALE, Calif., Sept 30, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Pharmacyclics, Inc. (Nasdaq: PCYC) today announced that it has provided Nasdaq with a plan and timetable as described below, which it believes will achieve compliance with Nasdaq Marketplace Rule 4350(d)(2), which requires Nasdaq-listed companies to have an Audit Com...
|
|
|
Pharmacyclics, Inc. Announces Board and Management Transitions
Sep 11, 2008
|
15.4 KB
|
| |
SUNNYVALE, Calif., Sept 11, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Pharmacyclics, Inc. (the "Company" or "Pharmacyclics") announced today that Christine A. White, M.D., Richard M. Levy Ph.D., Mr. Miles R. Gilburne and Richard A. Miller, M.D. have resigned as members of the Board of Directors of the Company, effective immediately. Th...
|
|
|
Pharmacyclics Reports Fourth Quarter and Fiscal 2008 Financial Results
Aug 14, 2008
|
15.1 KB
|
| |
SUNNYVALE, Calif., Aug 14, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Pharmacyclics, Inc. (Nasdaq: PCYC) today reported financial results for its fourth quarter and fiscal year ended June 30, 2008. The net loss for the fourth quarter of fiscal 2008 was $4.6 million, or $0.18 per share, compared to a net loss of $7.0 million, or $0.27 pe...
|
|
|
Pharmacyclics Announces Conference Call to Discuss Fourth Quarter and Fiscal 2008 Year-End Results
Aug 7, 2008
|
8.4 KB
|
| |
SUNNYVALE, Calif., Aug 07, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Pharmacyclics, Inc. (Nasdaq: PCYC) today announced that it will hold a conference call to discuss its fourth quarter and fiscal 2008 year-end financial results and achievements, and 2009 guidance on Thursday, August 14, 2008, at 4:30 p.m. EDT (1:30 p.m. PDT).
To p...
|
|
|
Pharmacyclics Novel Btk Inhibitor Shows Efficacy in Preclinical Models of Rheumatoid Arthritis and Lymphoma
Jun 9, 2008
|
11.5 KB
|
| |
SUNNYVALE, Calif., June 9, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Pharmacyclics, Inc. (Nasdaq: PCYC) today announced results from a preclinical study evaluating PCI-32765, an orally available, selective inhibitor of Bruton's tyrosine kinase, or Btk, in collagen induced arthritis, an established animal model for rheumatoid arthritis ...
|
|
|
Phase 1/2 Trial of Motexafin Gadolinium Plus Antibody Targeted Radiation Therapy Demonstrates High Complete Response Rate in Patients With Non-Hodgkin's Lymphoma
Jun 5, 2008
|
12.4 KB
|
| |
SUNNYVALE, Calif., June 5, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Pharmacyclics, Inc. (Nasdaq: PCYC) today announced final data from a Phase 1/2 study showing a 46 percent complete response rate in patients with multiply recurrent non-Hodgkin's lymphoma (NHL) who were treated with motexafin gadolinium (MGd, Xcytrin(R)) in combinatio...
|
|
|
Pharmacyclics Announces It Received Nasdaq Notice of Compliance
May 30, 2008
|
8.0 KB
|
| |
SUNNYVALE, Calif., May 30, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Pharmacyclics, Inc. (Nasdaq: PCYC) today announced that it has received notice from The Nasdaq Stock Market that the company has regained compliance with Marketplace Rule 4450(a)(5) (the "Rule") relating to the maintenance of a minimum $1.00 bid price of the Company's...
|
|
|
Pharmacyclics Files Schedule 14D-9 Statement with Securities and Exchange Commission
May 14, 2008
|
9.6 KB
|
| |
SUNNYVALE, Calif., May 14, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Pharmacyclics, Inc. (Nasdaq: PCYC) announced today that it has filed a Schedule 14D-9 Solicitation/Recommendation Statement with the Securities and Exchange Commission (the "Commission"), as required by the Commission's rules, in response to an unsolicited tender offe...
|
|
|
Pharmacyclics Reports Third Quarter 2008 Financial Results
Apr 24, 2008
|
14.6 KB
|
| |
SUNNYVALE, Calif., April 24, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Pharmacyclics, Inc. (Nasdaq: PCYC) today reported financial results for its third fiscal quarter ended March 31, 2008. The net loss for the third quarter of fiscal 2008 was $7.0 million, or $0.27 per share, compared to a net loss of $6.8 million, or $0.26 per share,...
|
|
|
Pharmacyclics Announces It Received Nasdaq Notification
Apr 21, 2008
|
8.1 KB
|
| |
SUNNYVALE, Calif., April 21, 2008 /PRNewswire via COMTEX News Network/ -- SUNNYVALE, Calif., April 21 /PRNewswire-FirstCall/-- Pharmacyclics, Inc. (Nasdaq: PCYC) today announced that it received a Nasdaq staff deficiency letter on April 17, 2008 indicating that, for the last 30 consecutive days, the bid price for Pharmacyclics' common stock has clo...
|
|
|
Pharmacyclics' Novel Factor VIIa Inhibitor Demonstrates Potential Inhibition of Tumor Growth in Multiple Types of Cancer
Apr 16, 2008
|
11.3 KB
|
| |
SAN DIEGO and SUNNYVALE, Calif., April 16, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Pharmacyclics, Inc. (Nasdaq: PCYC) today presented preclinical results demonstrating the anti-tumor activity of PCI-27483, the company's small-molecule Factor VIIa inhibitor. The data were presented during the Annual Meeting of the American Association...
|
|
|
Pharmacyclics Reports Multiple Presentations at AACR on Its HDAC and Selective HDAC Inhibitors
Apr 15, 2008
|
12.4 KB
|
| |
SAN DIEGO and SUNNYVALE, Calif., April 15, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Pharmacyclics, Inc. (Nasdaq: PCYC) today announced preclinical data from four presentations at the Annual Meeting of the American Association for Cancer Research (AACR) being held this week in San Diego, CA. Results from multiple preclinical studies on...
|
|
|
Pharmacyclics Announces Conference Call to Discuss Third Quarter 2008 Financial Results
Apr 14, 2008
|
8.3 KB
|
| |
SUNNYVALE, Calif., April 14, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Pharmacyclics, Inc. (Nasdaq: PCYC) today announced that it will hold a conference call to discuss its third quarter 2008 financial results and achievements on Thursday, April 24, 2008, at 4:30 p.m. EDT (1:30 p.m. PDT).
To participate in the conference call, plea...
|
|
|
Pharmacyclics Announces Preclinical Results Supporting Development of Its Novel Btk Inhibitor in Immune Mediated Diseases
Apr 14, 2008
|
11.0 KB
|
| |
SAN DIEGO and SUNNYVALE, Calif., April 14, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Pharmacyclics, Inc. (Nasdaq: PCYC) today presented results from its preclinical program evaluating PCI-32765, an orally available, selective inhibitor of Bruton's tyrosine kinase, or Btk, in B-cell receptor (BCR) modulated diseases such as lymphomas an...
|
|
|
Pharmacyclics Announces Multiple Presentations at the American Association for Cancer Research Annual Meeting
Apr 3, 2008
|
11.9 KB
|
| |
SUNNYVALE, Calif., April 3, 2008, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Pharmacyclics, Inc. (Nasdaq: PCYC) today announced multiple presentations on its novel oncology and autoimmune disease drug candidates at the American Association for Cancer Research (AACR) 2008 Annual Meeting being held April 12-16, 2008, at the San Diego Conv...
|
|
|
Pharmacyclics Realigns to Focus on Advancing Expanded Pipeline of Promising Product Candidates
Feb 28, 2008
|
12.0 KB
|
| |
SUNNYVALE, Calif., Feb 28, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Pharmacyclics, Inc. (Nasdaq: PCYC) today announced a corporate realignment to reduce expenses and focus its activities on advancing its expanded pipeline of promising new product candidates that address large market opportunities in cancer and immune-mediated diseases...
|
|
|
Pharmacyclics Announces Data and Publication Characterizing Highly-Selective HDAC Inhibitor
Feb 11, 2008
|
10.9 KB
|
| |
SUNNYVALE, Calif., Feb 11, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Pharmacyclics, Inc. (Nasdaq: PCYC) today announced publication of data characterizing the company's novel highly-selective histone deacetylase (HDAC) inhibitor. The study, entitled "A novel histone deacetylase 8 (HDAC8)-specific inhibitor PCI-34051 induces apoptosis i...
|
|
|
Pharmacyclics Reports Second Quarter 2008 Financial Results
Jan 24, 2008
|
13.8 KB
|
| |
SUNNYVALE, Calif., Jan 24, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Pharmacyclics, Inc. (Nasdaq: PCYC) today reported financial results for its second fiscal quarter ended December 31, 2007. The net loss for the second quarter of fiscal 2008 was $5.9 million, or $0.23 per share, compared to a net loss of $6.0 million, or $0.25 per sha...
|
|
|
